TY - JOUR

T1 - Sumatriptan does not change calcitonin gene-related peptide in the cephalic and extracephalic circulation in healthy volunteers

AU - Hansen, Jakob Møller

AU - Petersen, Jesper

AU - Wienecke, Troels

AU - Olsen, Karsten Skovgaard

AU - Jensen, Lars Thorbjørn

AU - Ashina, Messoud

AU - Hansen, Jakob Møller

AU - Petersen, Jesper

AU - Wienecke, Troels

AU - Olsen, Karsten Skovgaard

AU - Jensen, Lars Thorbjørn

AU - Ashina, Messoud

N1 - Keywords: Adult; Analysis of Variance; Calcitonin Gene-Related Peptide; Cerebrovascular Circulation; Female; Humans; Injections, Subcutaneous; Male; Radioimmunoassay; Serotonin Agonists; Sumatriptan; Young Adult

PY - 2009

Y1 - 2009

N2 - Triptans are effective and well tolerated in acute migraine management but their exact mechanism of action is still debated. Triptans might exert their antimigraine effect by reducing the levels of circulating calcitonin gene-related peptide (CGRP). To examine this question, we examined whether sumatriptan modulate the baseline CGRP levels in vivo, under conditions without trigeminovascular system activation. We sampled blood from the internal and external jugular, the cubital veins, and the radial artery before and after administration of subcutaneous sumatriptan in 16 healthy volunteers. Repeated-measure ANOVA showed no interaction between catheter and time of sampling and thus no significant difference in CGRP between the four catheters (P=0.75). CGRP did not change over time in the four compartments (P>0.05). The relative changes in CGRP between baseline and maximal sumatriptan concentration did not differ between the four vascular compartments (P=0.49). It was found that Sumatriptan did not change the levels of circulating CGRP in the intra or extracerebral circulation in healthy volunteers. This speaks against a direct CGRP-reducing effect of sumatriptan in vivo in humans when the trigemino vascular system is not activated.

AB - Triptans are effective and well tolerated in acute migraine management but their exact mechanism of action is still debated. Triptans might exert their antimigraine effect by reducing the levels of circulating calcitonin gene-related peptide (CGRP). To examine this question, we examined whether sumatriptan modulate the baseline CGRP levels in vivo, under conditions without trigeminovascular system activation. We sampled blood from the internal and external jugular, the cubital veins, and the radial artery before and after administration of subcutaneous sumatriptan in 16 healthy volunteers. Repeated-measure ANOVA showed no interaction between catheter and time of sampling and thus no significant difference in CGRP between the four catheters (P=0.75). CGRP did not change over time in the four compartments (P>0.05). The relative changes in CGRP between baseline and maximal sumatriptan concentration did not differ between the four vascular compartments (P=0.49). It was found that Sumatriptan did not change the levels of circulating CGRP in the intra or extracerebral circulation in healthy volunteers. This speaks against a direct CGRP-reducing effect of sumatriptan in vivo in humans when the trigemino vascular system is not activated.

U2 - 10.1007/s10194-009-0102-x

DO - 10.1007/s10194-009-0102-x

M3 - Journal article

C2 - 19266171

VL - 10

SP - 85

EP - 91

JO - Journal of Headache and Pain

JF - Journal of Headache and Pain

SN - 1129-2369

IS - 2

ER -